Pharma Pulse 8/23/24: Drug Coverage Changes in Medicare Part D Plans, Law That Shielded Big Tech Now Being Used Against It & more

Increasing Diversity with the Integrated Research Model

In part 1 of this video interview, Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara highlights how IROs are bringing care directly to patients and making them feel more comfortable.

Study Finds Drug Coverage Changes in Medicare Part D Plans

Avalere’s Kylie Stengel talks about the regional shifts in formularies and utilization management in Medicare Part D prescription drug plans.

How a Law That Shields Big Tech Is Now Being Used Against It

A Massachusetts professor has filed a lawsuit against Meta using a novel interpretation of Section 230, a law known primarily for shielding social media companies from liability.

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine

Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY® (COVID-19 Vaccine, mRNA), and granted emergency use authorization for individuals 6 months through 11 years of age (Pfizer-BioNTech COVID-19 Vaccine) of the companies’ Omicron KP.2-adapted 2024-2025 Formula COVID-19 vaccine. This season’s vaccine is for use as a single dose for most individuals 5 years of age and older. Individuals 5 years of age and older with certain kinds of immunocompromise previously vaccinated with Pfizer and BioNTech COVID-19 vaccines or children under the age of 5 who have not already completed a three-dose series with previous formulas of a COVID-19 vaccine may be eligible to receive additional doses.

Mike Christel on LinkedIn

I enjoyed speaking with veteran biopharma leader Ken Keller about his journey from sales rep to CEO of Daiichi Sankyo US—and the advent of next-generation ADCs in changing the future of cancer treatment. “In oncology, we're not here to just bring another drug to the market. In today’s world, that doesn't work. Every decision we make is what can we do to elevate the standard of care,” Keller told me for a profile in Pharmaceutical Executive. Check it out if you have a few minutes.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs